associated risk

Vueklar Cardiovascular does have a large range of products from Stents for biliary,urological,gastrointeslinal and bronchial.Heart valves,Septal occluders,Vena cava filters,Left Atial Appendage closure devices,Vascular closure devices,Stent Biopsy needles as well Guide wires,Catheters and balllons for opening artery.Plus they own over 50 Patents with 40 been granted cover over multiple types of implants
The main points that need to be taken into account are
The risk associated with resonance health moving from Non invasive technology company that has been derisk to a large degree to a company that performs or supply invasive equipment used in surgery.
There also the risk that the stent technology may not receive FDA,TGA or CE approval.
There the Dilution effect that would occur with the aquistion plus the on going costs of getting the product to market and maintaining Personnel.
Will this business be a stand alone business within the resonance Health group or will they drain funds from the rest of the group to fund further development of the stent technology.
I do believe if this aquistion happen the risk profile of Resonance Health will increase Ten fold and the grading of the stock will be adjusted from investment grade to spec Grade.